This study aimed to evaluate the safety and efficacy of local sclerosant injection in the treatment of pyogenic granuloma.

A retrospective analysis was performed on patients with pyogenic granuloma admitted to the Interventional Vascular Anomalies Department of our hospital from February 2022 to December 2024. Based on the appearance of the lesion and its basal dimensions, patients were classified into broad-stalk and narrow-stalk types. The broad-stalk type was treated with a combination of ligation using silk thread and injection of a sclerosant, whereas the narrow-stalk type received only the sclerosant injection. Treatment outcomes, incidence of complications, number of treatment sessions, and recurrence rates were analyzed to assess the clinical effectiveness of the treatment.

Among the 15 patients included, 9 with the narrow-stalk type underwent sclerosant injection, and 6 with the broad-stalk type received the combined treatment of silk thread ligation and injection of a sclerosant (either 1% polidocanol or Lauromacrogol). Complete resolution of the lesions was achieved within 8 weeks following treatment. Only 1 patient required 2 sessions of local injection, while the remaining patients were successfully treated with a single session. All patients tolerated the treatment well, and no adverse reactions such as allergic responses or skin necrosis were observed. During a follow-up period ranging from 2 to 24 months, no recurrences were noted, and no post-healing pigment deposition or scar formation was observed.

Local sclerosant injection is a highly effective and safe treatment modality for pyogenic granuloma. For broad-stalk lesions, the addition of ligation may further enhance therapeutic outcomes.